Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated Clinuvel's CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about Clinuvel's vitiligo program.

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated Clinuvel's CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about Clinuvel's vitiligo program.

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated Clinuvel’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about Clinuvel's vitiligo program

Erythropoietic protoporphyria (EPP) is a rare disease causing absolute intolerance of skin to light. In about 5% of EPP cases, patients also experience liver failure, requiring a life saving liver transplant. Florence, an immunology PhD, career scientist and EPP patient, underwent a liver transplant in 1989 following a liver failure due to her EPP. In early 2012 Florence shared her story on camera, discussing her transplantation in depth. Clinuvel is very grateful to Florence for being able to share this online.

Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide, common understanding of vitiligo has been clouded by misconceptions, leading to the stigmatization of those affected by the disease. Modern medical understanding easily corrects much of this misunderstanding. In presenting this information we hope to facilitate a better common understanding of vitiligo, and to help people gain an insight into this distressing disorder. Produced March 2012. Learn more about Clinuvel's vitiligo program. Quote references: Vitiligo Support International: http://www.vitiligosupport.org/vitiligo/ Kaimal & Thappa, (2010). "Diet in Dermatology". IJDVL 76(2):103-115. Available online: http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=2;spage=103;epage=115;aulast=Kaimal Gauthier & Benzekir in Picardo & Taieb (2010). "Vitiligo". Springer (1st edition). Image references: http://commons.wikimedia.org/wiki/File:Vitiligo1.JPG http://commons.wikimedia.org/wiki/File:Vitiligo2.JPG Selected images courtesy of Pearl E Grimes MD Our thanks to Hedvig…

On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes absolute intolerance of skin to sunlight, and Clinuvel’s novel drug SCENESSE® (afamelanotide), which has been trialed as a photoprotective in EPP. Clinuvel has subtitled the 'Check up' program and re-released for the broader EPP community.All footage and soundtrack are copyright © Telezueri 2012.

Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medicines Agency, CEO Dr Philippe Wolgen discusses the challenges to date and what may lie ahead for Clinuvel.

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain forces him into living a nocturnal life or enduring outdoor activities in great discomfort or pain. Isolation and unrelenting pain from sun exposure greatly impacts the quality of life of EPP patients. With no effective treatment currently available to them, sun avoidance is their only option. Forced to remain indoors, EPP patients eventually succumb to a nocturnal existence, the only way of life for many porphyria patients. Throughout his life Mikey has been unable to experience the outdoor activities that many take for granted without the protection of clothing that completely blocks the sun such as a boiler suit, balaclava and gloves. Socialising with friends is difficult and "the pain just isn't worth it"…

There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include: applying a damp towel to sunburnt areas, cool baths, medication, topical ointments and keeping hydrated. If you have any of the following symptoms you may have acute sunburn: *Severe burns *Deep reddening *Extensive blistering *Strong pain *Dizziness or light headedness *Headaches *Nausea or vomiting *Chills or fever In cases of acute sunburn, seek immediate medical treatment. Sunburn is the visible, physical response of the skin to damage by overexposure to UV radiation; the severity of your sunburn will depend on the intensity and duration UV radiation exposure and often damaged skin cells are beyond repair. It’s important to protect your skin from sunlight and UV in order to prevent sunburn and…